{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:46:15Z","timestamp":1789055175006,"version":"build-2803163510"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>During the COVID-19 pandemic, elderly patients with underlying condition, such as tumors, had poor prognoses after progressing to severe pneumonia and often had poor response to standard treatment. Mesenchymal stem cells (MSCs) may be a promising treatment for patients with severe pneumonia, but MSCs are rarely used for patients with carcinoma. Here, we reported a 67-year-old female patient with lung adenocarcinoma who underwent osimertinib and radiotherapy and suffered from radiation pneumonitis. Unfortunately, she contracted COVID-19 and that rapidly progressed to severe pneumonia. She responded poorly to frontline treatment and was in danger. Subsequently, she received a salvage treatment with four doses of MSCs, and her symptoms surprisingly improved quickly. After a lung CT scan that presented with a significantly improved infection, she was discharged eventually. Her primary disease was stable after 6 months of follow-up, and no tumor recurrence or progression was observed. MSCs may be an effective treatment for hyperactive inflammation due to their ability related to immunomodulation and tissue repair. Our case suggests a potential value of MSCs for severe pneumonia that is unresponsive to conventional therapy after a COVID-19 infection. However, unless the situation is urgent, it needs to be considered with caution for patients with tumors. The safety in tumor patients still needs to be observed.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1321236","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:53:14Z","timestamp":1707195194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaohua","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingshu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101825","article-title":"Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis","volume":"37","author":"Jutzeler","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e40148","DOI":"10.7759\/cureus.40148","article-title":"The rise of SARS-CoV-2 (COVID-19) omicron subvariant pathogenicity","volume":"15","author":"DeGrasse","year":"2023","journal-title":"Cureus"},{"key":"B3","unstructured":"Clinical management of COVID-19: Living guideline, 13 January 20232023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26424","article-title":"Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes","volume":"93","author":"Li","year":"2021","journal-title":"J Med Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15532","article-title":"Factors associated with mortality in patients with COVID-19 admitted to intensive care: A systematic review and meta-analysis","volume":"76","author":"Taylor","year":"2021","journal-title":"Anaesthesia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa168","article-title":"Clinical characteristics and outcomes of COVID-19-infected cancer patients: A systematic review and meta-analysis","volume":"113","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Institute"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2210880","DOI":"10.1001\/jamanetworkopen.2022.10880","article-title":"Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: A systematic review and meta-analysis","volume":"5","author":"Khoury","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B8","unstructured":"Therapeutics and COVID-19: Living guideline, 13 January 20232023"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3565","article-title":"Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among u.s. Veterans: Target trial emulation studies with one-month and six-month outcomes","volume":"176","author":"Bajema","year":"2023","journal-title":"Ann Internal Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45010028","article-title":"A clinical update on SARS-CoV-2: Pathology and development of potential inhibitors","volume":"45","author":"Singh","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13054-022-04205-8","article-title":"Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (bari-SolidAct): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"27","author":"Tr\u00f8seid","year":"2023","journal-title":"Crit Care (London England)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Internal Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2021.0049","article-title":"Recent trends in multipotent human mesenchymal stem\/stromal cells: Learning from history and advancing clinical applications","volume":"25","author":"Dzobo","year":"2021","journal-title":"Omics: J Integr Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158196","article-title":"Immunomodulation of mesenchymal stem cells in acute lung injury: From preclinical animal models to treatment of severe COVID-19","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Sengupta","year":"2020","journal-title":"Stem Cells Dev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13287-021-02165-4","article-title":"Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: A case series","volume":"12","author":"Hashemian","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10214-x","article-title":"Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey","volume":"17","author":"OE","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s13287-021-02483-7","article-title":"Cell therapy in patients with COVID-19 using wharton\u2019s jelly mesenchymal stem cells: A phase 1 clinical trial","volume":"12","author":"Saleh","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10398-w","article-title":"Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia","volume":"18","author":"Chu","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932360","article-title":"Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: Preliminary results of a phase i\/II clinical trial","volume":"13","author":"Gr\u00e9goire","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13287-022-02900-5","article-title":"Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: A pilot study","volume":"13","author":"Zhu","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: A phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-022-02920-1","article-title":"Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: A successful phase 1, control-placebo group, clinical trial","volume":"13","author":"Kaffash Farkhad","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1002\/ctm2.297","article-title":"Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial","volume":"11","author":"Xu","year":"2021","journal-title":"Clin Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13287-022-02953-6","article-title":"Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase i clinical trial): Safety profile assessment","volume":"13","author":"Aghayan","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","article-title":"Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells","volume":"11","author":"Shu","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/09636897211024942","article-title":"The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: A prospective double controlled trial","volume":"30","author":"Adas","year":"2021","journal-title":"Cell Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.21-0046","article-title":"Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial","volume":"10","author":"Dilogo","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13287-022-02771-w","article-title":"Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: Clinical trial phase i & II","volume":"13","author":"Fathi-Kazerooni","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13287-022-02812-4","article-title":"Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: A randomized, double-blind, placebo-controlled trial","volume":"13","author":"Karyana","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13054-022-03930-4","article-title":"Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: A multicenter randomized double-blind trial","volume":"26","author":"Monsel","year":"2022","journal-title":"Crit Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13287-022-02796-1","article-title":"Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: A randomized clinical trial","volume":"13","author":"Rebelatto","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0157OC","article-title":"A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19","volume":"207","author":"Bowdish","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104370","article-title":"Prognostic value of interleukin-6, c-reactive protein, and procalcitonin in patients with COVID-19","volume":"127","author":"Liu","year":"2020","journal-title":"J Clin Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221608","article-title":"Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19","volume":"195","author":"Schwartz","year":"2023","journal-title":"CMAJ: Can Med Assoc J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0291178","DOI":"10.1371\/journal.pone.0291178","article-title":"Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis","volume":"18","author":"Wu","year":"2023","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00072","article-title":"Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: A systematic review and meta-analysis","volume":"7","author":"Nadkarni","year":"2021","journal-title":"JCO Global Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet (London England)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164896","article-title":"COVID-19-related ARDS: Key mechanistic features and treatments","volume":"11","author":"Selickman","year":"2022","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.931061","article-title":"Mechanism of COVID-19 causing ARDS: Exploring the possibility of preventing and treating SARS-CoV-2","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S405722","article-title":"SARS-CoV-2 n protein triggers acute lung injury via modulating macrophage activation and infiltration in in vitro and in vivo","volume":"16","author":"Lai","year":"2023","journal-title":"J Inflammation Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.600160","article-title":"Molecular crosstalk between macrophages and mesenchymal stromal cells","volume":"8","author":"Stevens","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/ijms24043376","article-title":"Key role of mesenchymal stromal cell interaction with macrophages in promoting repair of lung injury","volume":"24","author":"Jerkic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-023-03277-9","article-title":"Superior protective effects of PGE2 priming mesenchymal stem cells against LPS-induced acute lung injury (ALI) through macrophage immunomodulation","volume":"14","author":"Hezam","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01560-8","article-title":"Defining the role of natural killer cells in COVID-19","volume":"24","author":"Lee","year":"2023","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00557-9","article-title":"Unique immunological profile in patients with COVID-19","volume":"18","author":"Varchetta","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1574888x13666180912125736","article-title":"Mesenchymal stromal cells and natural killer cells: A complex story of love and hate","volume":"14","author":"Najar","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030825","article-title":"CuMV VLPs containing the RBM from SARS-CoV-2 spike protein drive dendritic cell activation and Th1 polarization","volume":"15","author":"Sebasti\u00e3o","year":"2023","journal-title":"Pharmaceutics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13287-023-03408-2","article-title":"Dendritic cells mediated by small extracellular vesicles derived from MSCs attenuated the ILC2 activity via PGE2 in patients with allergic rhinitis","volume":"14","author":"Liu","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2017.0078","article-title":"Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the notch-1\/jagged-1 signaling pathway","volume":"26","author":"Xu","year":"2017","journal-title":"Stem Cells Dev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.imlet.2020.03.005","article-title":"Mesenchymal stem cells induced regulatory dendritic cells from hemopoietic progenitor cells through notch pathway and TGF-\u03b2 synergistically","volume":"222","author":"Li","year":"2020","journal-title":"Immunol Lett"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02410-z","article-title":"Mesenchymal stem cells activate notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury","volume":"18","author":"Lu","year":"2020","journal-title":"J Transl Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","article-title":"Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury","volume":"10","author":"Lu","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02538","article-title":"Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function","volume":"9","author":"Reis","year":"2018","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010033","article-title":"Mesenchymal stromal cells-derived extracellular vesicles regulate dendritic cell functions in dry eye disease","volume":"12","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41590-021-00985-3","article-title":"Significance of bystander t cell activation in microbial infection","volume":"23","author":"Lee","year":"2022","journal-title":"Nat Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ t cell activation and early immune pathology distinguish severe COVID-19 from mild disease","volume":"54","author":"Bergamaschi","year":"2021","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1108716","article-title":"Lung t cell response in COVID-19","volume":"14","author":"Shakiba","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2022.12.008","article-title":"Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation","volume":"31","author":"Yunis","year":"2023","journal-title":"Trends Microbiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13287-020-01826-0","article-title":"Overexpression of TGF\u03b21 in murine mesenchymal stem cells improves lung inflammation by impacting the Th17\/treg balance in LPS-induced ARDS mice","volume":"11","author":"Chen","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41419-023-05597-3","article-title":"Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing t-cell immunosuppression","volume":"14","author":"Liao","year":"2023","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","article-title":"The germinal centre b cell response to SARS-CoV-2","volume":"22","author":"Laidlaw","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular b cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05273-0","article-title":"Dysregulated naive b cells and de novo autoreactivity in severe COVID-19","volume":"611","author":"Woodruff","year":"2022","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01156","article-title":"B lymphocytes as targets of the immunomodulatory properties of human amniotic mesenchymal stromal cells","volume":"11","author":"Magatti","year":"2020","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01843","article-title":"The immunomodulatory effects of mesenchymal stem cells on regulatory b cells","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13287-020-01934-x","article-title":"Immunosuppressive effects of mesenchymal stem cells on lung b cell gene expression in LPS-induced acute lung injury","volume":"11","author":"Feng","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121845","article-title":"Molecular pathogenesis of fibrosis, thrombosis and surfactant dysfunction in the lungs of severe COVID-19 patients","volume":"12","author":"Krygier","year":"2022","journal-title":"Biomolecules"},{"key":"B74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biochi.2022.11.011","article-title":"Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications","volume":"207","author":"Williams","year":"2023","journal-title":"Biochimie"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054273","article-title":"Clinical-scale mesenchymal stem cell-derived extracellular vesicle therapy for wound healing","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/rme-2018-0020","article-title":"The effect of mesenchymal stem cell-secreted factors on airway epithelial repair","volume":"14","author":"Halim","year":"2019","journal-title":"Regener Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/ijms19102996","article-title":"Human mesenchymal stem cell secretome from bone marrow or adipose-derived tissue sources for treatment of hypoxia-induced pulmonary epithelial injury","volume":"19","author":"Shologu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e13692","DOI":"10.7717\/peerj.13692","article-title":"Bone mesenchymal stem cell-derived exosomes prevent hyperoxia-induced apoptosis of primary type II alveolar epithelial cells in vitro","volume":"10","author":"Yang","year":"2022","journal-title":"PeerJ"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.114537","article-title":"Human umbilical cord mesenchymal stem cell-derived extracellular vesicles alleviated silica induced lung inflammation and fibrosis in mice via circPWWP2A\/miR-223-3p\/NLRP3 axis","volume":"251","author":"Hou","year":"2023","journal-title":"Ecotoxicol Environ Saf"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2019.7965","article-title":"Mesenchymal stem cell-derived extracellular vesicles attenuate radiation-induced lung injury via miRNA-214-3p","volume":"35","author":"Lei","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"B81","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13046-022-02351-z","article-title":"Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT\/GSK3\u03b2 pathway via c-MET in radiation-induced lung injury","volume":"41","author":"Li","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e21429","DOI":"10.1097\/md.0000000000021429","article-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13287-020-01802-8","article-title":"A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: A clinical case report","volume":"11","author":"Peng","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0810-9","article-title":"Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19","volume":"14","author":"Tang","year":"2020","journal-title":"Front Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.13081","article-title":"Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient","volume":"14","author":"Tao","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"B86","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13287-020-01725-4","article-title":"Intravenous infusion of human umbilical cord wharton\u2019s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia","volume":"11","author":"Zhang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-046573","article-title":"Remestemcel-l therapy for COVID-19-associated multisystem inflammatory syndrome in children","volume":"147","author":"Eckard","year":"2021","journal-title":"Pediatrics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2020_139","article-title":"Mesenchymal stem cells treatment in COVID-19 patient with multi-organ involvement","volume":"121","author":"Yilmaz","year":"2020","journal-title":"Bratisl Lek Listy"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.06.018","article-title":"Expanded mesenchymal stem cells: A novel therapeutic approach of SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain","volume":"155","author":"Soler Rich","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2021.62.288","article-title":"Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: A case report","volume":"62","author":"Primorac","year":"2021","journal-title":"Croat Med J"},{"key":"B91","doi-asserted-by":"publisher","first-page":"228","DOI":"10.12688\/f1000research.51191.2","article-title":"Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia","volume":"10","author":"Putra","year":"2021","journal-title":"F1000Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1177\/09636897211021008","article-title":"Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe COVID-19: Case report","volume":"30","author":"Senegaglia","year":"2021","journal-title":"Cell Transplant"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szac067","article-title":"Efficacy of MSC in patients with severe COVID-19: Analysis of the literature and a case study","volume":"11","author":"Grumet","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/medicina58121698","article-title":"Effectiveness of mesenchymal stem cell therapy for COVID-19-induced ARDS patients: A case report","volume":"58","author":"Kim","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2022.103454","article-title":"Human placenta-derived mesenchymal stromal cells transfusion in a critically ill infant diagnosed with coronavirus disease 2019 (COVID-19): A case report","volume":"61","author":"Payandeh","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963445","article-title":"Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case reports following hematopoietic cell transplantation and a review","volume":"13","author":"Sadeghi","year":"2022","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103789","article-title":"Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Shi","year":"2022","journal-title":"EBioMedicine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4015039","article-title":"The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche","volume":"2017","author":"Rivera-Cruz","year":"2017","journal-title":"Stem Cells Int"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3997","article-title":"Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor \u03b21","volume":"11","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0734-1","article-title":"Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT)","volume":"124","author":"Martin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0538","article-title":"Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12935-021-02300-4","article-title":"Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance","volume":"21","author":"Xuan","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25619","article-title":"Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12","volume":"128","author":"Lis","year":"2011","journal-title":"Int J Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2019.4344","article-title":"Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13","volume":"20","author":"Zhang","year":"2020","journal-title":"Bosnian J Basic Med Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0101","article-title":"Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling","volume":"2","author":"Li","year":"2012","journal-title":"Cancer Discov"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4630","article-title":"Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous Malignant transformation","volume":"69","author":"R\u00f8sland","year":"2009","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: A meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1321236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:53:17Z","timestamp":1707195197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1321236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2024.1321236"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1321236","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"article-number":"1321236"}}